Abstract
Pancreatic ductal adenocarcinoma (PDAC), accounting for more than 90% of all pancreatic malignancies, and the fourth most frequent cause of cancer-related mortalities worldwide with a 5-year overall survival of less than 8%. The main molecular trait of this deadly disease is the MAPK pathway activation due to KRAS mutation. The KRASG12C, an oncogenic driver mutation in PDAC, was studied to identify potential therapeutic candidates.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
